StockWatch
·

BERYL DRUGS LTD. Q4 FY25 Results

BERLDRGQ4 FY25 Results
Filing
MetricValue ( Cr)vs Q3 FY25
Revenue3.9725.1%
Total Income5.223.4%
Expenditure5.122.4%
PBT0.1036.8%
Net Profit0.15192.1%
OPM-18.84%11.96pp
NPM2.91%1.95pp
EPS0.30200.0%
View full financials

Informational and educational content only. Not investment advice.